RVTYNYSE

REVVITY, INC.

Laboratory Analytical Instruments · MA · CIK 31791

Revvity provides health science solutions, technologies, and services for discovery, development, diagnosis, and cure

🔥 High media attention

+ Watch View on EDGAR ↗

$11.12B

Market cap

$111.21

Last close

-1.6%

+12.3%

2.0M

Volume

Price · last 39 sessions+28.6%

May 4L $86.51 · H $113.53Jun 29

262

Total filings

Jun 23, 2026

Last filing

12/29

Fiscal year end

All 8-K · 132 10-Q · 43 DEFA14A · 18 DEF 14A · 15 11-K · 15 10-K · 15 SC 13G · 12 424B5 · 10

SC 13GSC 13GNov 14, 2024 SC 13GJANUS NEWNov 14, 2024 SC 13GSC 13GOct 11, 2022 SC 13GSC 13GFeb 10, 2022 SC 13GSCHEDULE 13GFeb 14, 2018 SC 13G

Similar companies

Comparable business profile · signals at a glance

TECHBIO-TECHNE Corp🔥$8.5B-0.1%AAGILENT TECHNOLOGIES, INC.🔥$36.7B-2.3%AZTAAzenta, Inc.$1.0B+0.0%QDELQuidelOrtho Corp$963.5M+32.2%QTRX

Insider Activity

In the 90 days to Feb 24, 2026: 5 sold $4.7M.

Date	Insider	Action	Shares	Price	Value
Feb 24, 2026	Victor MiriamePlease See Remarks	Sell	1,862	$97.13	$181K
Feb 23, 2026	Mcmurry-Heath MichelleDirector	Sell	600	$97.26	$58K
Feb 5, 2026	Singh Prahlad R.Please See Remarks	Sell	12,186	$99.55	$1.2M
Feb 5, 2026	Singh Prahlad R.Please See Remarks	Sell	7,885	$100.63	$793K
Feb 5, 2026	Goldberg Joel SPlease See Remarks	Sell	6,424	$99.47	$639K
Feb 5, 2026	Goldberg Joel SPlease See Remarks	Sell	3,544	$100.50	$356K
Feb 5, 2026	Singh Prahlad R.Please See Remarks	Sell	3,079	$101.45	$312K
Feb 5, 2026	Goldberg Joel SPlease See Remarks	Sell	2,217	$101.33	$225K
Feb 5, 2026	Singh Prahlad R.Please See Remarks	Sell	1,307	$99.02	$129K
Feb 5, 2026	Singh Prahlad R.Please See Remarks	Sell	1,068	$102.52	$109K
Feb 5, 2026	Goldberg Joel SPlease See Remarks	Sell	532	$102.52	$55K
Feb 2, 2026	Vohra Tajinder SPlease See Remarks	Sell	5,756	$104.50	$602K

Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.

What Changed

Risk factors · Feb 25, 2025 → Feb 24, 2026

23 added · 11 removed between the two most recent 10-Ks. The risks a company starts — or stops — disclosing are often the story.

Newly disclosed

Our competitiveness could also be negatively impacted by our failure to timely develop or deploy AI in our products and services, particularly if our competitors are successful in AI advancements in their products and services.
There is uncertainty related to the legal and regulatory landscape surrounding rapidly evolving AI technologies, particularly in the areas of cybersecurity, intellectual property, and privacy and data protection.
Tariffs implemented during fiscal year 2025 increased our cost of revenue by approximately $25 million and reduced our gross margin by approximately $20 million, primarily affecting products manufactured in Europe for the U.S. market.
AI algorithms utilized in the deployment may be flawed or based on datasets that are biased or insufficient, and do not adequately take into account the underlying nature of our business.
Uncertainties related to the development, deployment and use of AI to advance our product offerings and improve internal operations may result in harm to our business and reputation.
The development and deployment of AI presents both risks and opportunities, and the implementation process could adversely impact the operations of our business as a whole.
Failure to adequately train our employees during the deployment of AI could adversely impact our business or result in delays or errors in our offerings.
We are advancing AI across our product and service offerings, and we are in the initial phases of expanding AI into the core functions of our business.
In 2025, this commitment was reflected in our Great Place to Work certifications across India, China, Poland, and the United States with Euroimmun also certified in Brazil.
The development of AI technology will require significant investment in resources and human capital and could increase our costs.
The people experience survey provides additional validation as a substantial majority of our employees report pride in working for Revvity and feel encouraged to innovate and share new ideas, a powerful indicator of shared purpose across our global workforce.
R ecently announced and proposed changes in U.S. funding and regulations have created a more cautious spending environment for our customers and could cause them to become more conservative with both instrumentation and consumable purchases due to funding and regulatory uncertainty.

No longer disclosed

The site showcases our commitment to responsible business practices and how these contribute to long-term value creation for our stakeholders. 12 Table of Contents We understand that our ability to operate in a multicultural world is critical to our long-term value creation.
For our intellectual property that is protected by keeping it secret, such as trade secrets and know-how, we may not use adequate measures to protect this intellectual property. 17 Table of Contents Third parties have in the past and may in the future also challenge the validity of our issued patents, may circumvent or “design around” our patents and patent applications, or claim that our products, processes or technologies infringe their patents.
We are subject to stringent data privacy and information security laws and regulations and changes in such laws or regulations, or our failure to comply with such requirements, could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.
We believe that our business will continue to be subject to increasing regulation as the federal government continues to strengthen its position on healthcare matters, the scope and effect of which we cannot predict.
During fiscal year 2024, our voluntary turnover rate was approximately 9%.
We compete on the basis of service level, price, technological innovation, operational efficiency, product differentiation, product availability, quality and reliability.
Our growth and profitability are subject to global economic and political conditions, and operational disruptions at our facilities.
We are also required to meet specified financial ratios under the terms of certain of our existing debt instruments.
We do not maintain any key person life insurance policies on any of our officers or employees.

REVVITY, INC.

Similar companies

Insider Activity

In the News

What Changed